# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary Shelley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI028-SYN-TD
- Date: 1849-09-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosamund Achterberg-Ilesanmi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review after resection: seizures, mood, and writing. **S**

## History of present illness

Ms. Shelley returns about six months after resection of her meningioma. She has had no seizure since starting levetiracetam, about six and a half months ago, including during the stomach illness in August, when she vomited one dose. She drives again, keeps regular hours, and drinks little. Her mood is good; she finished her course with the counselor after eight sessions and says she can now speak of her old griefs without being undone by them. She writes every morning and has nearly finished her travel book. She has no headaches. **S**

| Element | Detail |
|---|---|
| Seizures | None since starting levetiracetam |
| Mood | Good; counseling completed after eight sessions |
| Writing | Every morning; travel book nearly finished |
| Gastroenteritis | Resolved in four days |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No seizures, aura, headaches, or weakness |
| Gastrointestinal | Negative | Bowels normal since August |
| Psychiatric | Negative | Mood good; no irritability; no thoughts of suicide |
| Constitutional | Negative | Weight stable; sleeping well |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice a day **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for headache or wound pain, no more than 3000 mg a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 57.4 kg; BMI 22.4 kg/m². All vital signs are synthetic.

PHQ-9: 4; MoCA: 29; Creatinine: 0.76 mg/dL; eGFR: 95 mL/min/1.73 m². All results are synthetic.

## Change since baseline

- PHQ-9: 7 at baseline, 4 at this visit **S**
- MoCA: 27 at baseline, 29 at this visit **S**
- Creatinine: 0.74 mg/dL at baseline, 0.76 mg/dL at this visit **S**
- eGFR: 98 mL/min/1.73 m² at baseline, 95 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Neurological | Normal: speech, strength, finger tapping, reflexes, and gait |
| Mental status | Bright, articulate, and reflective; MoCA 29 |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy on levetiracetam** (G40.109). Seizure-free for six and a half months; kidney function normal (creatinine 0.76 mg/dL, eGFR 95). PHQ-9 4; MoCA 29. **S**
   - Continue levetiracetam 500 mg twice a day.
   - At one year after surgery: EEG and a shared decision about tapering.
2. **Meningioma, CNS WHO grade 1, after resection** (D32.0). No symptoms of recurrence. **S**
   - MRI one year after surgery.
3. **Viral gastroenteritis** (A08.4). Resolved without complications or seizures. **S**
   - Keep the plan for vomited doses in her diary.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Seizure diary, triggers (sleep loss, alcohol, missed doses), and seizure first aid | Every visit | Completed today | No seizures in six and a half months; one vomited dose in August was managed by plan |
| Survey | PHQ-9, with a question about irritability on levetiracetam | Every visit while on levetiracetam and during cancer treatment | Completed today | 4, minimal; counseling completed |
| Survey | GAD-7 | Every visit during the diagnostic and treatment phase; then as needed | Not indicated | Mild at the last visit and no anxiety reported now; to be repeated if symptoms return |
| Survey | Cognitive screen after brain surgery | Baseline and after treatment | Completed today | MoCA 29, up from 27 before surgery |
| Laboratory | Kidney function on levetiracetam | Baseline, then periodically, because the drug is cleared by the kidneys | Completed today | Creatinine 0.76 mg/dL; eGFR 95 |
| Imaging | Surveillance MRI | Yearly for five years after the three-month scan | Due | One year after surgery |
| Examination | EEG before any taper | Before deciding to stop an antiseizure medicine | Due | At one year after surgery |

## Goal progress

- A diagnosis within two weeks, explained in plain words with the images and reports. Outcome by 1849-03-17: MRI and EEG within a week; diagnosis explained at two weeks with the images. **S**
- No further seizures. In progress; target 1850-04-07. **S**
- Full use of the right hand and return to writing every morning. Outcome by 1849-09-29: Grip equal on both sides by three months; writing every morning. **S**
- Decide on treatment herself after hearing the options, benefits, and harms. Outcome by 1849-03-17: Chose resection after observation and radiosurgery were explained. **S**
- Mood and grief supported: PHQ-9 below 5 and a counselor available. Outcome by 1849-09-29: PHQ-9 4 at six months; completed eight sessions with the neuro-oncology counselor. **S**

## Guideline basis

- EANO guideline on the diagnosis and management of meningiomas. Goldbrunner R, et al. Neuro Oncol 2021;23(11):1821-1834 (2021), European Association of Neuro-Oncology
- Evidence-based guideline: Management of an unprovoked first seizure in adults. Krumholz A, et al. Neurology 2015;84(16):1705-1713 (2015), American Academy of Neurology and American Epilepsy Society
- SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Walbert T, et al. Neuro Oncol 2021;23(11):1835-1844 (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (depression screening and PHQ-9 follow-up) (2026), Aether Forge

## Follow-up

- Preventive visit next month; MRI and EEG at one year after surgery with a review of levetiracetam. **S**
- Next scheduled visit 1849-10-20: adult preventive visit. **S**
